Yazar "Kuran, Sara Azra" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Nanotechnology-enabled miRNA delivery systems next-generation molecular strategies in cancer therapy
    (Academic Press Inc Elsevier Science, 2025) Kuran, Sara Azra; Adiyil, Rumeysa; Ziksahna, Kaan; Ozkan, Melisa; Ihlamur, Murat
    MicroRNAs (miRNAs) regulate cancer-relevant pathways but are limited clinically by instability, immune activation, and inefficient uptake. Nanotechnology offers platforms that protect and target miRNAs to tumors while enabling controlled release and intracellular delivery. This review focuses on lipid-based systems (including functionalized lipid nanoparticles (LNPs)), polymeric nanoparticles, dendrimers, and responsive hydrogels/ nanogels, emphasizing comparative performance and translational readiness. We outline key barriers-enzymatic degradation, rapid clearance, endosomal trapping, off-target effects, and manufacturability-and highlight practical solutions such as poly (ethylene glycol) (PEG) coating (PEGylation)/stealthing to prolong circulation, ligand-directed targeting to enhance specificity, ionizable/fusogenic chemistries for endosomal escape, and standardized evaluation to improve reproducibility. Recent preclinical studies illustrate meaningful antitumor activity and improved tolerability for several platforms, while clinical experiences underscore the need for rigorous safety assessment and scalable production. We conclude with a concise roadmap that prioritizes platform selection for near-term translation and integration with tumor-specific miRNA signatures to advance personalized therapy. Our translation-first synthesis links barriers to design solutions (pKatuned LNPs; exosome-mimetic/hybrid vesicles) and highlights AI/ML-guided formulation; lessons from MRX34/ TargomiRs inform safety, scalability, and CMC-together yielding a practical 24-36-month roadmap toward clinical readiness, with functionalized LNPs best positioned for near-term translation.
  • [ X ]
    Öğe
    VACCINE STUDIES TARGETING MELANOMA
    (Biruni Üniversitesi, 2025) Oymak, Sanem; Yavuz, Feyza; Kuran, Sara Azra; Zıkşahna, Kaan; Dinçer, Zeynep Yaren; Adıyıl, Rumeysa; Ihlamur, Murat
    Melanoma is a malignancy of melanocytic origin that has particular importance among skin cancers due to its high metastatic potential and mortality. Although surgery, chemotherapy, radiotherapy, and targeted therapies achieve partial success in melanoma, treatment resistance, relapse, and systemic adverse effects highlight the ongoing need for novel immunotherapeutic approaches. Cancer vaccines have emerged as strategies that aim to reduce tumor burden and prevent recurrence by inducing specific humoral and cellular immune responses against tumor cells or tumor-associated antigens. In this review, the current status of vaccine studies targeting the immune system in the treatment of melanoma is comprehensively evaluated within the framework of mRNA-based vaccines, dendritic cell (DC) vaccines, and neoantigen-based personalized vaccine strategies. Preclinical animal models and clinical studies involving patients with metastatic melanoma reported in the literature demonstrate that mRNA and DC vaccines can effectively activate CD4? and CD8? T cells, slow tumor growth, and provide clinical responses in selected cases. However, the genetic heterogeneity of melanoma, immune escape mechanisms, appropriate antigen selection, optimization of adjuvants and delivery systems, and issues related to manufacturing and cost constitute major limitations. Current evidence indicates that melanoma vaccines, particularly when combined with other immunotherapies such as immune checkpoint inhibitors, have the potential to contribute meaningfully to treatment; however, well-designed clinical trials involving larger patient cohorts are needed before these approaches can be incorporated into routine clinical practice.